Hematopoietic Cell Transplantation in the Treatment of Newly Diagnosed Adult Acute Myeloid Leukemia: An Evidence-Based Review from the American Society of Transplantation and Cellular Therapy

Bhagirathbhai Dholaria*, Bipin N. Savani, Betty K. Hamilton, Betul Oran, Hien D. Liu, Martin S. Tallman, Stefan Octavian Ciurea, Noa G. Holtzman, Gordon L.Phillips II, Steven M. Devine, Gabriel Mannis, Michael R. Grunwald, Frederick Appelbaum, Cesar Rodriguez, Firas El Chaer, Nina Shah, Shahrukh K. Hashmi, Mohamed A. Kharfan-Dabaja, Zachariah DeFilipp, Mahmoud AljurfAl Fadel AlShaibani, Yoshihiro Inamoto, Tania Jain, Navneet Majhail, Miguel Angel Perales, Mohamad Mohty, Mehdi Hamadani, Paul A. Carpenter, Arnon Nagler

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

41 Scopus citations

Abstract

The role of hematopoietic cell transplantation (HCT) in the management of newly diagnosed adult acute myeloid leukemia (AML) is reviewed and critically evaluated in this evidence-based review. An AML expert panel, consisting of both transplant and nontransplant experts, was invited to develop clinically relevant frequently asked questions covering disease- and HCT-related topics. A systematic literature review was conducted to generate core recommendations that were graded based on the quality and strength of underlying evidence based on the standardized criteria established by the American Society of Transplantation and Cellular Therapy Steering Committee for evidence-based reviews. Allogeneic HCT offers a survival benefit in patients with intermediate- and high-risk AML and is currently a part of standard clinical care. We recommend the preferential use of myeloablative conditioning in eligible patients. A haploidentical related donor marrow graft is preferred over a cord blood unit in the absence of a fully HLA-matched donor. The evolving role of allogeneic HCT in the context of measurable residual disease monitoring and recent therapeutic advances in AML with regards to maintenance therapy after HCT are also discussed.

Original languageEnglish
Pages (from-to)6-20
JournalBiology of Blood and Marrow Transplantation
Volume27
Issue number1
DOIs
StatePublished - Jan 2021
Externally publishedYes

Funding

FundersFunder number
ADC Therapeutics
Inctye Corp.
Incyte Corporation
TeneoBio
Bristol-Myers Squibb
GlaxoSmithKline
Merck
Sanofi
Janssen Research and Development
Janssen Biotech
Spectrum Pharmaceuticals
Celgene
Astellas Pharma Global Development
Takeda Pharmaceuticals U.S.A.
Takeda Pharmaceutical Company
GlaxoSmithKline Australia
Daiichi Sankyo Company

    Keywords

    • Acute myelogenous leukemia
    • Acute myeloid leukemia
    • Adult
    • Bone marrow transplantation
    • Chemotherapy
    • Cytogenetics
    • Disease status
    • Graft-versus-host disease
    • Hematopoietic cell transplantation
    • Leukemia risk
    • Measurable residual disease
    • Mutations
    • Relapse
    • Therapy

    Fingerprint

    Dive into the research topics of 'Hematopoietic Cell Transplantation in the Treatment of Newly Diagnosed Adult Acute Myeloid Leukemia: An Evidence-Based Review from the American Society of Transplantation and Cellular Therapy'. Together they form a unique fingerprint.

    Cite this